Sonoma Pharmaceuticals, Inc.
SNOA · XNASCIK 1367083fmd_1MK3KXMQQSRYZX4CDWS28YEJXQManufacturing · Surgical & Medical Instruments & ApparatusTemplate: Standard
Coverage: Apr 01, 2010 to Sep 30, 2026, 66 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 13 | 17 | 19 | 18 | 19 | 13 | 13 | 13 | 14 | 20 |
| Cost of revenue | 7 | 9 | 10 | 10 | 12 | 9 | 9 | 8 | 9 | 12 |
| Net interest income | – | – | – | – | 0 | (0) | 0 | – | – | – |
| Gross profit | 6 | 7 | 9 | 8 | 7 | 4 | 4 | 5 | 5 | 7 |
| Realized investment gains (losses) | – | – | – | – | – | – | – | – | – | – |
| Research and development | 2 | 2 | 2 | 1 | 1 | 0 | 0 | 2 | 2 | 2 |
| Selling, general and administrative | 17 | 20 | 19 | 14 | 9 | 10 | 9 | 8 | 7 | 8 |
| Total operating expenses | 19 | 21 | 20 | 16 | 10 | 10 | 9 | 9 | 9 | 10 |
| Operating income | (13) | (14) | (11) | (7) | (3) | (6) | (5) | (5) | (4) | (2) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | – | – | – | – | – |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | – | – | – | – | – |
| Income before taxes | (13) | (14) | (11) | (4) | (4) | (5) | (5) | (5) | (3) | (3) |
| Income tax expense | (4) | 0 | 0 | 0 | 1 | (0) | (0) | (0) | 1 | (0) |
| Net income from continuing operations | (9) | (14) | (12) | (4) | (5) | (5) | (5) | (5) | (3) | (3) |
| Net income | 9 | (14) | (12) | (3) | (4) | (5) | (5) | (5) | (3) | (3) |
| Net income to common shareholders | – | – | – | – | – | – | – | – | – | – |